ArticleFrontiers in pediatrics2026
Amino acid-based formula with synbiotics for cow's milk protein allergy: a real-world study of symptom evolution and quality-of-life outcomes.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cow's milk protein allergy (CMPA) is a common early-life food allergy. Evidence from routine care settings may complement randomized trials by describing symptom trajectories in heterogeneous populations. Objective: This study aimed to describe changes in symptom scores and caregiver-reported outcomes over 28 days following initiation of an amino acid-based formula containing synbiotics in infants with suspected or confirmed CMPA in routine practice. Methods: This was a prospective, multicenter, observational, single-arm real-world cohort study. Physicians recorded cow's milk allergy symptom score (CoMiSS) and infant gastrointestinal symptom questionnaire (IGSQ-13) at baseline (Day 1) and Day 28. Caregivers completed the atopic dermatitis patient-oriented score (PO-SCORAD) and quality of life in food allergy-parental burden (FAQL-PB) at baseline and Day 28 and recorded stool, regurgitation, and discomfort at prespecified time points. One-year outcomes (growth and health resource use) were assessed descriptively among participants with available follow-up data. Results: A total of 71 infants completed the 28-day observation period. Mean CoMiSS decreased from 10.1 (SD 4.6) at baseline to 3.5 (SD 2.2) on Day 28. Median IGSQ-13 and PO-SCORAD scores decreased over 28 days; FAQL-PB scores also decreased. Caregiver-reported stool frequency and regurgitation categories improved over time. One-year outcomes were available for 56 children and are reported descriptively. Conclusion: In this prospective real-world cohort, symptom scores and caregiver-reported outcomes improved over 28 days following initiation of an amino acid-based formula containing synbiotics in infants managed for suspected/confirmed CMPA. Given the observational nature of the study, these findings should be interpreted cautiously and do not establish causality or comparative effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.